You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Screen for hepatitis B virus in all cancer patients starting systemic treatment. Find out more about hepatitis B virus screening and management.

Drug Formulary
About the Drug Formulary Email Drug Formulary Team

What’s New in the Drug Formulary

All new and recently updated drug and regimen monographs, patient information sheets, as well as safety and advice documents are available here.

Drug

Published Date: 01 Apr 2026

Revision Summary:
Drug Monograph: Removed NDFP funding information
Updated
Apr 2026
Drug

Published Date: 31 Mar 2026

Revision Summary:
Drug Monograph: New drug monograph
Patient Info Sheet EN: New drug information sheet
Patient Info Sheet FR: New information sheet (Nouvelle fiche d'information)
Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Removed "Unfunded" info from bendamustine

Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Modified Rationale/uses section; Removed bendamustine NDFP funding info

Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Removed bortezomib NDFP funding info

Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Removed bortezomib NDFP funding info

Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Removed bortezomib NDFP funding info; Removed "unfunded" bortezomib status for cycles 5 and 6

Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Removed bortezomib NDFP funding info; Removed "unfunded" bortezomib status for cycles 5 and 6

Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:
Regimen Monograph: Modified Rationale/uses section; Removed bortezomib NDFP funding info
Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Removed bortezomib NDFP funding info

Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Intent: Palliative
Revision Summary:

Regimen Monograph: Removed bortezomib NDFP funding info

Updated
Mar 2026
Regimen
Published Date: 31 Mar 2026
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Revision Summary:

Regimen Monograph: Removed bortezomib NDFP funding info

Updated
Mar 2026

Pages